SCHEMBL8107074

SCHEMBL8107074

CC(O)OC(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.46
ADRA2C P18825 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ADRA2A P08913 2/20 0.46
HIF1A Q16665 1/20 0.46
ALDH1A1 P00352 2/20 0.45
CHRM2 P08172 2/20 0.43
ADRA1A P35348 2/20 0.43
CYP2D6 P10635 2/20 0.43
TSHR P16473 2/20 0.43
HTR2A P28223 2/20 0.43
THPO P40225 2/20 0.43
RGS12 O14924 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670224 0.80 SCN1A (0.42) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL12227917 0.80 SCN1A (0.42) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL127629 0.79 IDO1 (0.46) LMNAKDM4EADRA2ACHRM2ADRA1A
Hydrochloric Acid SCHEMBL28591682 0.79 KDM4E (0.52) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL19984489 0.78 SLC6A4 (0.44) ADRA2CADRA2AALDH1A1ADRA1ATSHR
SCHEMBL11835643 0.78 TSHR (0.48) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL8775673 0.77 LMNA (0.43) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL9619659 0.77 LMNA (0.43) LMNAADRA2CKDM4EADRA2AHIF1A
Water SCHEMBL11878861 0.76 IDO1 (0.44) LMNAKDM4EADRA2ACHRM2ADRA1A
Ammonia Solution, Strong SCHEMBL7282272 0.76 IDO1 (0.44) LMNAKDM4EADRA2ACHRM2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed
EP-0613880-A1 Agent and method for the immunological determination of Diphenhydramine and its metabolites MERCK PATENT GmbH (DE) 1994-09-07 EP disclosed